Indication Tooltip

LORBRENA® (lorlatinib) is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC)

  • that is caused by an abnormal anaplastic lymphoma kinase (ALK) gene, and
  • that has spread to other parts of the body, and
  • who have taken the medicine:
    • alectinib, or ceritinib, or
    • both crizotinib and at least 1 other medicine to treat NSCLC that is caused by the ALK gene, and
  • that is no longer responding to these treatments.

It is not known if LORBRENA is safe and effective in children.

The effectiveness of LORBRENA is based on a study that measured tumor response rate and duration of response. There is an ongoing study to find out how LORBRENA works over a longer period of time.

About
the Disease

ANAPLASTIC LYMPHOMA KINASE (ALK)+ NON-SMALL CELL LUNG CANCER (NSCLC)

magnifying glass icon

Our Understanding of ALK+ NSCLC Is Evolving

For years, lung cancer was thought to be a single illness linked to smoking. But science has taught us that lung cancer is a complex disease with many types and subtypes. It can develop in men and women of different ages and races, regardless of whether they've ever smoked.

One subtype of lung cancer is ALK+ NSCLC. Living with ALK+ NSCLC can be challenging and sometimes discouraging, especially if it continues to grow or spread (progresses). If it does, you should know that there are certain therapies called ALK inhibitors that may help you. Some of them may be effective even after you've already taken one or more prior ALK inhibitors.

The ALK Fusion Gene

Everyone has the ALK gene in each of their cells. If part of the ALK gene breaks off and reattaches the wrong way, it can create an ALK fusion gene. This may cause the cell to multiply out of control, resulting in cancer growth.

Because there are ALK inhibitor treatments available, doctors can create treatment plans specifically for people with ALK+ NSCLC that has spread (metastasized).

 

lungs-icon

NSCLC accounts for 80% to 85% of all lung cancer cases; 3% to 5% of people with NSCLC test positive for the ALK fusion gene.

 

 

understanding alk+ nsclc progression

How and Why Progression Happens

Many ALK+ NSCLC tumors initially respond to ALK inhibitor therapy, but then develop changes that allow them to continue to grow despite treatment. When this resistance to therapy happens, the disease can progress.

If your disease has progressed while taking an ALK inhibitor therapy, talk to your doctor about other treatment options available to you, including LORBRENA®.

 

 

Monitoring Disease Progression

Whether or not your lung cancer has continued to progress, life with ALK+ NSCLC may seem to center around waiting: When is the next scan? What are the next scan results going to be? Will the cancer progress? These constant concerns, sometimes referred to as “scanxiety,” may be overwhelming.

Thanks to breakthroughs in NSCLC research, there is a biomarker-driven treatment approved for use in people whose disease has progressed after they had received alectinib or ceritinib, or crizotinib and at least 1 other ALK inhibitor medicine.

ALK=anaplastic lymphoma kinase; NSCLC=non-small cell lung cancer.

Pfizer Oncology Together Call 1-877-744-5675 Visit PfizerOncologyTogether.com